Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, 48149, Germany.
Neurologic Clinic and Policlinic, Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Ann Clin Transl Neurol. 2021 Apr;8(4):944-950. doi: 10.1002/acn3.51334. Epub 2021 Mar 1.
We determined activation profiles of the classical and alternative complement pathway in 39 treatment-naïve patients with early relapse-onset MS. Plasma concentrations of complement fragments were unchanged in MS compared to 32 patients with non-inflammatory neurological diseases. Profiles in patients experiencing clinical exacerbations did not differ from patients with stable disease and did not correlate with baseline EDSS, numbers of T2 lesions and time to second relapse. Long-term EDSS outcomes 4 years after diagnosis did not significantly correlate with baseline complement levels. These data do not support the use of complement activation products as biomarkers for disease activity in early MS.
我们在 39 例初发复发型 MS 患者中确定了经典和替代补体途径的激活谱。与 32 例非炎症性神经疾病患者相比，MS 患者的补体片段血浆浓度无变化。经历临床恶化的患者的特征与病情稳定的患者无差异，且与基线 EDSS、T2 病变数量和第二次复发时间均无相关性。诊断后 4 年的长期 EDSS 结局与基线补体水平无显著相关性。这些数据不支持将补体激活产物用作早期 MS 疾病活动的生物标志物。
